• 1
    Shibata A, Ma J, Whittemore AS. Prostate cancer incidence and mortality in the United States and the United Kingdom. J. Natl. Cancer Inst. 1998; 90: 12301.
  • 2
    Bartsch G, Horninger W, Klocker H et al. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology 2001; 58: 41724.
  • 3
    Bill-Axelson A, Holmberg L, Ruutu M et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N. Engl. J. Med. 2005; 352: 197784.
  • 4
    Kamoi K, Babaian RJ. Advances in the application of prostate-specific antigen in the detection of early-stage prostate cancer. Semin. Oncol. 1999; 26: 1409.
  • 5
    Catalona WJ, Partin AW, Slawin KM et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998; 279: 15427.
  • 6
    Suzuki H, Akakura K, Igarashi T et al. Clinical usefulness of serum anti-p53 antibodies for prostate cancer detection: a comparative study with PSA parameters. J. Urol. 2004; 171: 1826.
  • 7
    Carlson GD, Calvanese CB, Partin AW. An algorithm combining age, total prostate-specific antigen (PSA), and percent free PSA to predict prostate cancer: results on 4298 cases. Urology 1998; 52: 45561.
  • 8
    Eastham JA, May R, Robertson JL, Sartor O, Kattan MW. Development of a nomogram that predicts the probability of a positive prostate biopsy in men with an abnormal digital rectal examination and a prostate- specific antigen between 0 and 4 ng/mL. Urology 1999; 54: 70913.
  • 9
    Potter SR, Horniger W, Tinzl M, Bartsch G, Partin AW. Age, prostate-specific antigen, and digital rectal examination as determinants of the probability of having prostate cancer. Urology 2001; 57: 11004.
  • 10
    Ohori M, Swindle P. Nomograms and instruments for the initial prostate evaluation: the ability to estimate the likelihood of identifying prostate cancer. Semin Urol. Oncol. 2002; 20: 11622.
  • 11
    Djavan B, Remzi M, Zlotta A, Seitz C, Snow P, Marberger M. Novel artificial neural network for early detection of prostate cancer. J. Clin. Oncol. 2002; 20: 9219.
  • 12
    Garzotto M, Hudson RG, Peters L et al. Predictive modeling for the presence of prostate carcinoma using clinical, laboratory, and ultrasound parameters in patients with prostate specific antigen <10 ng/mL. Cancer 2003; 98: 141722.
  • 13
    Yanke BV, Carver BS, Bianco FJ et al. African-American race is a predictor of prostate cancer detection: incorporation into a pre-biopsy nomogram. BJU Int. 2006; 98 (4): 7837.
  • 14
    Nam RK, Toi A, Klotz LH et al. Assessing individual risk for prostate cancer. J. Clin. Oncol. 2007; 25: 35828.
  • 15
    Cook LS, Goldoft M, Schwartz SM et al. Incidence of adenocarcinoma of the prostate in Asian immigrants to the United States and their descendants. J. Urol. 1999; 161: 1525.
  • 16
    Suzuki H, Komiya A, Kamiya N et al. Development of a nomogram to predict probability of positive initial prostate biopsy among Japanese patients. Urology 2006; 67: 1316.
  • 17
    Karakiewicz PI, Benayoun S, Kattan MW et al. Development and validation of a nomogram predicting the outcome of prostate biopsy based on patient age, digital rectal examination and serum prostate specific antigen. J. Urol. 2005; 173: 19304.
  • 18
    Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J. Natl. Cancer Inst. 1998; 90: 76671.
  • 19
    Chun FK, Graefen M, Briganti A et al. Initial biopsy outcome prediction—head-to-head comparison of a logistic regression based nomogram versus artificial neural network. Eur. Urol. 2007; 51: 123643.
  • 20
    Kawakami S, Numao N, Okubo Y et al. Development, validation, and head-to-head comparison of logistic regression-based nomograms and artificial neural network models predicting prostate cancer on initial extended biopsy. Eur. Urol. 2008 (Epub ahead of print).
  • 21
    Babaian RJ, Dinney CP, Ramirez EI et al. Diagnostic testing for prostate cancer detection: less is best. Urology 1993; 41: 4215.
  • 22
    Presti JC Jr, O'Dowd GJ, Miller MC, Mattu R, Veltri RW. Extended peripheral zone biopsy schemes increase cancer detection rates and minimize variance in prostate specific antigen and age related cancer rates: results of a community multi-practice study. J. Urol. 2003; 169: 1259.
  • 23
    Emiliozzi P, Scarpone P, DePaula F et al. The incidence of prostate cancer in men with prostate specific antigen greater than 4.0 ng/ml: a randomized study of 6 versus 12 core transperineal prostate biopsy. J. Urol. 2004; 171: 1979.
  • 24
    Inahara M, Suzuki H, Kojima S et al. Improved prostate cancer detection using systematic 14-core biopsy for large prostate glands with normal digital rectum examination. Urology 2006; 68: 8159.
  • 25
    Chun FK, Briganti A, Graefen M et al. Development and external validation of an extended 10-core biopsy nomogram. Eur. Urol. 2007; 52: 43644.
  • 26
    Chun FK, Briganti A, Graefen M et al. Development and external validation of an extended repeat biopsy nomogram. J. Urol. 2007; 177: 5105.
  • 27
    Remzi M, Djavan B, Wammack R et al. Can total and transition zone volume of the prostate determine whether to perform a repeat biopsy? Urology 2003; 61: 1616.
  • 28
    Remti M, Fong YK, Dobrovits M et al. The Vienna nomogram: validation of a novel biopsy strategy defining the optimal number of cores based on patient age and total prostate volume. J. Urol. 2005; 174: 125661.